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Abstract
Histone Deacetylase (HDAC) plays a vital role in cellular processes, for example
gene expression, cell growth, and apoptosis. Finding drug candidates to inhibit the over
activity of HDACs in cancer is a growing area of interest. Inhibitors, thus far, have three
important motifs to be studied: the zinc binding group, a hydrophobic linker, and a cap
group. By altering these groups on the inhibitor, not only can activity be increased but
also selectivity within the classes of HDACs. We present the design of two novel sets of
molecules that contain either a 1,2,3-triazole or 1,2,4-triazole. The 1,2,3-triazoles were
synthesized using “click chemistry” with a novel pyridyl triazine catalyst. The 1,2,4triazoles were synthesized utilizing substitution chemistry. This set of molecules was
designed after suberoylanilide hydroxamic acid (SAHA) but replaced the hydroxamate
with the triazole as the zinc binding group. The activity of these inhibitors against HDAC
1, HDAC 6, and SIRT 1 were tested using the Biomol Fluor de Lys in vitro kits. Though
none of the synthesized compounds were strong activators or inhibitors of any of the
classes of HDACs, trends were observed that could lead to the design of more potent
inhibitors.
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Introduction
Background and Mode of Action of HDACs
The aberrant expression of various genes is crucial to the onset and progression
of cancer. There is evidence that, not only can altering the Deoxyribonucleic acid (DNA)
sequence directly cause the onset of cancer but also epigenetic changes can affect the
cancer genome.1 These epigenetic changes can be observed by controlling the ‘open’
and ‘closed’ states of chromatin, i.e.-chromatin remodeling. Chromatin is a regular array
of nucleosomes and DNA linkers.2-4 Nucleosomes are comprised of a histone octamer
with double stranded DNA wrapping around the histones.5 The histones serve as
spindles for the DNA to be ordered and packaged around. They are paired with nonhistone proteins and DNA linkers to string the nucleosomes together forming
chromatin.6 The ‘open’ and ‘closed’ states of chromatin refer to reversible modification
of acetyl groups on the core histones. When the chromatin is ‘open’, transcription
machinery will have access to the DNA, thus enabling the DNA to be read and gene
expression to occur.2,3 In the ‘closed’ form DNA is no longer accessible, and thus the
gene expression is silenced.3,4,6
In Eukaryotic cells, these ‘open’ and ‘closed’ states are controlled by Histone
acetylation or deactylation. Histone acetylation is maintained by histone deacetylases
(HDACs) and histone acetyltransferases (HATs).5 HATs transfer the acetyl group from
acetyl-coenzyme A to the ε-amino groups of lysine residues at the N-terminal on core
histones.5,7 HDACs have an opposing role to remove the acetyl groups by hydrolysis
11

(Figure 1). This equilibrium process accounts for the above discussed gene expression,
specifically chromatin remodeling. When HDACs are active this leads to hypoacetylated
region of the chromatin, the amino groups are protonated and positively charged lysine
can interact electrostatically with the phosphate groups of the DNA.1,8 This causes the
DNA to be bound more tightly to the chromatin and gene silencing will occur. The
chromatin is unfolded when the HATs begin to reacetylate the lysine to removing the
electrostatic interactions between the amine functionality and the DNA (Figure 2).6,9
Post-translational control of chromatin is an emerging area of anti-cancer drug
design, focusing on HDAC regulation as a viable form of epigenetic and non-epigenetic
control.6 HDAC inhibition is the central focus over HATs due to the fact that HDACS are
more structurally diverse. This leads to a diversity of function and a wider array of
promising targets for drug discovery. Current research has shown that HDACs can also
form various complexes with additional proteins, allowing for non-epigenetic
modifications.

Figure 1:Histone Acetylation and Deacetylation with HAT and HDAC 8
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Figure 2: “Closed” vs “Open” chromatin during chromatin remodeling using HAT
and HDAC 9,10
HDAC can modify gene expression not only by altering chromatin but by forming
complexes with other proteins and by recruiting other transcription factors. A few
examples of HDAC complexes that still involve histone methylation or acetylation are
the Sin3 and NuRD (nucleosome remodeling and deacetylating) complexs.6 Sin3
contains RpAp46/48 with HDAC 1 and 2. The HDACs are recruited to the DNA which
leads to gene silencing by altering the DNA methylation/acetylation. A similar complex is
formed with NuRD with HDAC1 and HDAC2 and again mediates DNA methylation by
recruiting DNA methyltransferase1 (DNMT).6,11 Examples of non-histone modification
include direct complexation with transcription factors such as STAT3, tumor suppressor
genes such as p53, and cell cycle regulators such as RB (retinoblastoma protein).12
STAT3 can be directly acetylated and inactivated by HDAC1. Other coenzymes needed
for STAT3 transcription function can also be acetylated by HDAC1 or HDAC3 and
cause inactivation.6,12 Tumor suppressor gene p53 is also deacetylated by HDAC1,
HADC2 and/or HDAC3. P53 plays an important role in cell proliferation and gene
transcription by relying on its ability to bind DNA with a sequence specificity to activate
transcription. The down-regulation of the p53 activity is very dependent on which region
13

of p53 is acetylated and is HDAC dose dependent.13 RB also interacts with HADC
similarly to p53, by interacting with RB and other proteins that complex with RB that can
directly affect chromatin remodeling.6,14 There are several ways, epigenetic and nonepigenetic, HDACs can alter gene transcription leading to cancer regulation. But the
primary challenge in targeting HDACs is finding inhibitors that can have HDAC
specificity amongst the various classes.

Classes and Functions of HDACs
There are four major classes of HDACs, class I, IIa and IIb, III, and IV. Within the
four classes are 18 isozymes.3,14 Class I HDACs include HDAC1, HDAC2, HDAC3,
HDAC8. Class I HDACs are generally localized in the nucleus and are related to the
Rpd3 gene product.10 Class II HDACs can be split into two sub-classes: IIa which
includes HDAC4, HDAC5, HDAC7 and HDAC9 and sub-class IIb which includes
HDAC6 and HDAC10. Class IIa has a conserved C-terminal catalytic domain similar to
the HDAC1 yeast protein but the N-terminal domain has no similarity to HDACs in other
classes. Class IIb has an extra acetylase domain when compared to the HDAC1 yeast
protein. Class II HDACs primarily localize in the cytoplasm but can migrate from the
nucleus to the cytoplasm.6,14 Class III HDACs are the sirtuin family, these include SIRT1
through SIRT7. Class IV HDACs include HDAC 11 and are located in the cytoplasm and
nucleus but not known to shuttle between the two like class II HDACs.14 HDAC class IV
is the newest class of HDACs and has features of both class I and II HDACs.2 The
various HDAC classes also exhibit different functions as well as different localities within
the cell. (Table 1). 8,10,14
14

Table 1: HDACs expression sites and functions in cancer

2,9,15,16

HDAC class III isoforms are not related to class I and II in structure or function.
HDAC class I and II both contain zinc containing amide hydrolases and are zinc
dependent in their function. HDAC class III relies on NAD+ dependent amide hydrolases
and are zinc independent. Of the four HDAC classes, class I is the primary anti-cancer
drug target because it not only has epigenetic features but important non-epigenetic
control abilities as well. Examples include degrading the tumor suppressor gene p53,
which is active in apoptosis, DNA repair and overall cell cycle control.2,14

Types of HDAC Inhibitors
HDAC inhibitors have various anti-cancer functions and work on several different
forms of cancer. Because of their broad
15

spectrum of function, HDAC class I and II

inhibitors have been subdivided into four different classes: hydroxamates, aliphatic
acids, benzamides and cyclic peptides.17 There are a few molecules in particular that
have been highly studied in each class of inhibitors (Figure 2). Trichostatin A (TSA) and
Suberoyl anilide hydroxamic acid (SAHA, also known as vorinostat) are known HDAC
inhibitors in the hydroxamate family.3 SAHA is the first HDAC inhibitor to be approved
for clinical treatment.15 TSA shows reduction in tumor weight but it is not selective
enough to be approved by the FDA for clinical trials. SAHA on the other hand showed a
reduction in tumor weight, had a low abnormality in biochemical function rate, has
cancer selectivity (for T cell lymphoma), and when used in combination with other drugs
could enhance other forms of cancer therapy such as tumor radiation therapy.3,6
Valproic acid (VPA) is an example of the aliphatic acid inhibitors, MGCD0103 is an
example of the benzamide inhibitors and lastly FK-228 is a cyclic peptide inhibitor.2,15
The aliphatic acid inhibitors, benzamide inhibitors and the cyclic peptides have not
shown cancer selectivity in trials yet but are being tested in clinical trials for various
types of cancers.3 All of these inhibitors have shown therapeutic potential as
monotherapy or in combination with other anti-tumor drugs and are only active on
HDAC class I and II inhibition. HDAC class III (sirtuin inhibition) is dependent on NAD+.7
A common Class III inhibitor is nicotinamide but this has issues similar to TSA, it is not
very selective against cancer types, treatments, or sirtuin isoforms.

16

Figure 3: Commonly known HDAC inhibitors 2,6,18
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HDAC Typical Design Features
There are three typical requirements that need to be considered when designing
an HDAC inhibitor for class I or II: 1-) a zinc-binding group, capable of fitting into the
catalytic site and bind zinc(II), 2-) a linker group able to occupy the hydrophobic channel,
and 3-) a cap group to interact with sites on the surface of the HDAC (Figure 3).19 One
or more of these features can be changed to try to maximize isozyme selectivity and
overall HDAC inhibition. Common changes to the known inhibitors TSA or SAHA used
to make them more selective include: making the cap group more bulky by adding more
ring groups or a cyclic peptide at the end of the linker, adding substituents within or on
the linker region, and using heteroaromatic substituents as the zinc binding group.20
Some of these modified compounds did show more selectivity such as depsipeptide
(FK-228) and tubacin. Depsipeptide is a cyclic peptide and is selective towards HDAC1
and 2.3,6 Tubacin is very similar to SAHA but has a much bulkier cap group and is
selective towards HDAC6. By adding more cyclic groups, there is an increase of π-π
stacking allowing for a stronger interaction with phenylalanine and tyrosine residues that
are present in the linker and cap region of the HDAC binding site.20
The major HDAC inhibitors SAHA and TSA have the hydroxamate moiety as the
zinc binding group. The reason that hydroxamates can inhibit HDACs is a salt-bridge
can be formed from the hydroxamate to the positively charged zinc.6 Also, there are two
histidines, two tyrosines and an aspartic acid, that within the pocket interacts with the
hydroxamate.21,22

18

Figure 4: HDAC binding site: A: Drawing representing the HDAC binding sites
with SAHA. B: Crystal structure of HDAC8 bound to SAHA
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The histidine to aspartic acid interaction is a charge-relay system that is common
in active sites. These charge relays bind to the water adjacent to the zinc molecule. The
tyrosine is located directly next to the zinc atom and may also contribute to hydrogen
bonding. The hydroxamate can also hydrogen bond with the charge relay system and
the tyrosine hydroxyl group. The hydroxamate also replaces the water from the zinc and
interacts with the zinc using its carbonyl oxygens and the hydroxamate hydroxyl.6,21,22

SAHA Based Inhibitor Design
In designing molecules for this project SAHA was used as a template molecule
(Figure 3). It is a well known HDAC inhibitor and is currently being used in clinical
studies.3 The HDAC protein is the most flexible in the cap group region. Altering the cap
group is, in turn, the easiest part of the inhibitor to modify but does not lead to significant
isozyme selectivity because of the flexibility of the outside of the protein.23 Inside the
pocket is a much more rigid environment. Studies have shown that the linker is not
directly involved in the binding mechanism but by changing the linker or shape,
inhibition can be affected.23 If the linker is too long the cap group and/or zinc binding
group will not fit into their recognition site properly or at all.6,24
To improve the selectivity, the zinc binding group was the primary focus. SAHA
has a hydroxamate as its zinc binding group. Hydroxamates are easily hydrolyzed
under biological conditions, thus making them inaccessible to the zinc group in the
HDAC binding pocket, making it a poor drug candidate. While keeping the straight chain
alkane as the linker and a phenyl cap group, the zinc binding hydroxamate was
replaced by a 1,2,3-triazole with various

substituents.
20

Triazoles

have

been

proposed to be a non classical bioisostere of amides.25 A triazole binding group would
not be hydrolyzed under biological conditions. Also, the nitrogens in the triazole would
be better able to bind the zinc atom and to interact with the charge relay system.
Although the linker remains a straight alkyl chain, the length can be altered to
better fit the channel in between the cap group and the zinc binding group. An azidealkyne click reaction catalyzed by a novel catalyst (5,6-diphenyl-3-(pyridine-2-yl)-1,2,4triazine) with copper (I) was used to synthesize the 1,2,3-triazoles. Solution phase
synthesis was employed. The molecules were tested for inhibition activity purified or in
solution under click conditions against the following HDACs.

Designing Class Selective Inhibitors
Part of the aim of this project was to focus on the inhibition of each class of
histone deacetylases. HDAC1 (class I), HDAC2 (class II) and SIRT1 (Class III) were
chosen to experimentally represent the inhibition abilities of various molecules. HDAC6
being a class IIb HDAC is found in the cytoplasm.

Figure 5: SAHA as an Inhibitor Model: Replacing the zinc binding groups with
1,2,3-triazoles or using the classical hydroxamate zinc binding group
21

It is currently of interest because not only does HDAC6 deacetylate histone
proteins in chromatin to regulate transcription but it can also deacetylate some
nonhistone proteins, such as α-tubulin and HSP90.6,26 As mentioned earlier, these
nonhistone proteins are involved with cell signaling, cell growth, and tumor
suppression.6,24 These are all processes which need to be regulated during the course
of cancer. HDAC6 is thought to have two catalytic domains that work independently
from each other. These differing domains allow for more isozyme selectivity when it
comes to drug design due to the fact that the only other HDAC that may have two
domains is HDAC10. One of the binding domains is for the histone deacetylation and
one for the nonhistone deacetylation. Recently, HDAC6 has been shown to have a
great effect on myeloma cells. Thus, not only is the selective inhibition of HDAC6 of
interest because of its biological functions but also for its antitumor drug candidate
possibilities.

HDAC6 overexpression has mainly been observed in breast cancer.

Inhibition of HDAC6 leads to the depletion of pre-growth and survival of chaperone
proteins in cancer cells.2,6,16
HDAC1 is in the class I HDACs and is one of the more commonly studied
HDACs. HDAC1 is found in the nucleus and is directly related to proliferation, gene
regulation and apoptosis.24 Most class I HDACs are involved in proliferation and
chromatin remodeling but HDAC1 differs in the fact that it helps to regulate apoptosis by
deacetylating protein p53.24,27 HDAC1 over expression has been observed in prostate,
gastric, colon and breast cancer. Inhibition of HDAC1 in cancer cells results in inhibition
of proliferation and induction of autophagy. HDAC 6 and HDAC1 are strongly inhibited
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by TSA and SAHA. But only HDAC1 is inhibited strongly by valproic acid, MGCD0103,
and FK-228 when compared to the inhibition of HDAC6, which is only weakly inhibited
by these known inhibitors.2
SIRT1 is a class III HDAC inhibitor and differs from class I or II due to the fact
that it is dependent on NAD+. SIRT1 not only has histone deacetylase abilities but is
also known for its ADP-ribosyltransferase activity.2 ADP-ribosyltransferase is involved in
DNA repair and apoptosis, as well as histone modification. Sirtuin activity is linked to
NAD hydrolysis which forms nicotinamide.17 Sirtuin is thus its own regulator because it
forms its own inhibitor while acting in the cell. Sirtuin activity not only can be inhibited to
down regulate deacetylation but it can also be up regulated. This is caused by a
molecule that blocks the receptor site for nicotinamide, thus allowing sirtuin activity to
increase. The diversity in the molecules that can cause inhibition or activation of SIRT1
makes SIRT1 a good cancer target. The above HDACs are all readily available in a
fluorometric assay kit, Fluor de Lys, from biomol. 16,17

Fluor de Lys Assay Background
The Fluor de Lys assay is a one pot assay kit that is convenient and sensitive
enough to detect even slight HDAC inhibition. The assay is carried out in two easy steps.
During the first step the Fluor de Lys substrate, which has an acetylated lysine side
chain, is incubated with HDAC1 or HDAC 6 and the inhibitor being studied at 37 oC for
30 minutes. For SIRT1 NAD

+

is included in this first incubation step. When the

substrate is deacetylated it can then react with the developer (incubated at room
temperature for 45 minutes) in the second step to create a fluorophore. The samples
23

were excited at 360 nm and the emitted light was detected at 440 nm. This assay can
be performed in a 96 well plate or in microcentrifuge tubes and be transferred to an
appropriate cell for the fluorometer.

Design and Synthesis of 1,2,3- and 1,2,4-Triazoles as Zinc
Binding Groups
A series of SAHA-like compounds (3a-c, 4 a, 6a-b – Figure 7 and Figure 8) were
synthesized to determine if 1,2,3- or 1,2,4-triazoles could be used efficiently as zinc
binding groups. These compounds have the typical inhibitor layout: a cap group, alkyl
linker group, and a zinc binding group. Using a triazole as a zinc binding group should
offer a more robust moiety that can withstand biological conditions and allow for optimal
zinc binding.

Design and Synthesis of 1,2,3-triazoles:
The 1,2,3-triazoles have been used in a previous paper as a replacement of the
amide bond in SAHA that links the phenyl cap group to the alkyl linker (Figure 6).19,25

Figure 6: Known HDAC1 Inhibitors: from Chen et al.19
24

These papers show that the replacement of the amide bond did increase activity
but the activity was dependent on the linker length and what substituents were used as
the cap group.19 The triazole replacement was thought to make the cap group
interaction stronger with the various amino acids in the cap group region.19 In
compounds 3a-c and 4a (Figure 7) the amide bond was replaced with the 1,2,3-triazole
to give the most advantageous cap group recognition region. In our research design,
the 1,2,3-triazole was also used to replace the hydroxamate zinc binding group, as seen
in SAHA. In addition to replacing the amide bond and the hydroxamate binding group,
the linkers were varied to determine the optimal length needed to be active in the HDAC
or SIRT pocket. The 1,2,3-triazoles offer two adjacent nitrogens, along with ‘side-arms’
with alcohols that can assist in zinc binding.
The key reaction in synthesizing the 1,2,3-triazoles (Figure 7) was the use of
Cu(I) catalyzed “click chemistry” in the presence of 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4triazine (7a). This triazine ligand is a novel and readily used catalyst in the presence of
base and Cu(I) in organic solvent. The use of this catalyst increases the ‘sexiness’ of
“click chemistry” by resulting in a pure product. The column chromatography needed in
these reactions is primarily to remove the catalyst.

Design and Synthesis of 1,2,4-triazoles:
The 1,2,4-triazoles (6a, 6b – Figure 8) offer two possibilities for zinc binding. The
nitrogen atoms that are available are transversely placed which could allow for one
nitrogen to directly interact with the zinc molecule and the other nitrogen to interact with
the

amino

acids

(such

as

aspartic acid, and tyrosine).6 The other

histidine,
25

option would allow both nitrogen atoms to be used for zinc binding. The 1,2,4-triazoles
do not contain the ‘side-arms’ seen in the 1,2,3-triazoles. These ‘side-arms’ could cause
extra bulk in the binding pocket and not allow the nitrogen to appropriately interact with
the zinc molecule. With the differences between the 1,2,3- vs the 1,2,4-triazoles and by
using a combination of different linkers, cap groups and zinc binding groups it was
hypothesized that an isoform selective inhibitor would be designed.
The key reaction in forming the 1,2,4-triazoles (Figure 8) is a basic substitution
reaction in N,N-dimethylformamide (DMF) and potassium carbonate (K2CO3) at room
temperature. The substitution reaction is novel in the fact that, at room temperature
there is a regioselective preference for the reaction to occur at the 1 position and not the
4 position in the triazole. Through trial and error, it was observed that when the reaction
was heated (60-100 oC) there was a mixture of products with substitution at the one and
four positions.
To test the ability of the triazoles to be adequate zinc binding groups an in vitro
Fluor de Lys assay from BioMol was employed. This kit offers a convenient one pot
assay that can be used with a variety of HDAC and SIRT enzymes. HDAC1, HDAC6,
and SIRT1 were chosen to represent one of each type of the classes of HDACs, class I,
II and II respectively.

Results and Discussion
Enyzme Inhibition
SAHA like compounds with the typical hydroxamate zinc binding group being
26

replaced with a 1,2,3- or 1,2,4-triazole were synthesized and tested in the Fluor de Lys
assay. On initial evaluation, compounds 3a-c, 4a, and 6a-b were the most active
against inhibiting HDAC6 and can both activate and inhibit SIRT1.

HDAC1
There is no clear trend with the compounds in HDAC1 (Figure 9 and Figure 11).
There was some ‘negative’ inhibition numbers included in the HDAC1 data. These
numbers indicate that the enzyme was activated, an increase in activity was observed,
by the compound instead of inhibited. It was slightly surprising the activity did not show
more inhibiting properties. The compounds compared to the ones shown in Figure 6 are
very similar. The only differences being the compounds have a hydroxamate instead of
a triazole zinc binding group. This shows that for HDAC1 triazoles as the zinc binding
group does not increase inhibition.

Figure 7: 1, 2, 3, - Triazole for Zinc Binding Group Synthesis
27

Figure 8: 1, 2, 4 - Triazole for Zinc Binding Group Synthesis

SIRT1
The compounds appear to have a slight trend with SIRT1 depending on the type
of triazole (Figure 9 and Figure 13). In comparison of 3a-c and 4a, the smaller alkyl
linker shows inhibition where as the longer linker lead to activation of SIRT1 enzyme.
Compound 3a has the smallest linker is the only compound with a 1,2,3-triazole that
actually inhibits SIRT1. Between compounds 3b, 3c and 4a as the linker gets longer the
more activating abilities the compound has. Compound 4a not only has the longest
linker (6 carbons) but it also has two carbons between the triazole and the hydroxyl
group. This gives the ‘side-arm’ the more flexibility with the additional carbons and
probably a better ability to interact with the zinc molecule. The compounds without the
‘side-arms’, the 1,2,4-triazoles both have inhibiting properties. As the linker gets longer
with this set of compounds the more inhibition with SIRT1 is observed. The 1,2,4triazoles appear to have an opposing trend with SIRT1 than with the 1,2,3-triazoles.
Compound 6b has the strongest inhibition properties compared to both types of
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triazoles. None of the compounds are very strong activators or inhibitors compared to
the controls resveratrol and suramin sodium (Figure 10 and Figure 13). Resveratrol
causes a two hundred percent increase in activity of SIRT1. Suramin Sodium causes
one hundred percent inhibition of SIRT1.

HDAC6
The most inhibition out of all three studies is with HDAC6 (Figure 9 and Figure
12). Again the 1,2,4-triazoles appear to have an opposing trend from the 1,2,3-triazoles.
The 1,2,4-triazoles, compounds 6a-b, show that as the linker gets longer the percent
inhibition decreases. With the longer linker there is about 50 percent less inhibition than
with the shorter linker. The 1,2,3-triazoles, compounds 3a-c shows a positive correlation
between linker length and percent inhibition. Between the four and five carbon linker
there is not much of a difference in inhibition. The six carbon linker causes a three fold
increase in inhibition. The 1,2,3-triazole compound 4a has a six carbon linker and a two
carbon spacer between the triazole and the hydroxyl group. With the above trend in
compounds 3a-c it would be expected that 4a would be even more active due to the
increase in length but the inhibition decreases slightly. This compound may be too long
for the binding pocket. A selective known inhibitor for HDAC6 is tubacin (Figure 3).
Tubacin is very similar to SAHA in zinc-binding moiety but has a much larger cap group
region. This may help to explain why the largest percent inhibition is observed with the
1,2,3-triazoles. A 1,2,3-triaozle is present right before the phenyl group. Both of these
combined form a larger cap recognition region. The 1,2,3-triazoles are also similar to
the tubacin because they do not contain the
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amide

bond

that

SAHA

and

compounds 6a-b have. The increase in cap group size and the lack of the amide bond
is exploiting the capping group modifications more than the zinc binding group to cause
a HDAC class selective inhibition.

Selectivity
Determining if a compound is a strong inhibitor or activator is only half of the goal
when designing a drug target. More importantly, the molecule needs to be not only
active against the desired target but also selective. If the compound stops all HDAC
activity that can be just as detrimental to the disease as allowing the HDAC to be overly
active. These compounds show selectivity towards being able to inhibit HDAC6 over
HDAC1. There is no pattern present with HDAC1, whereas with HDAC6 there is a
strong inhibition pattern. The compounds could inhibit up to twenty times more against
HDAC6 than they could HDAC1. The compounds could also inhibit up to 5 times more
against HDAC6 than they could with SIRT1. The compounds also show selectivity
because they are able to activate SIRT1.
It is also interesting to note the selectivity between the different types of triazoles
in SIRT1 and HDAC6. With SIRT1, the 1,2,4-triazoles primarily inhibited SIRT1 where
as 1,2,3-triazoles activated SIRT1. The inhibition with HDAC6 can be controlled by
using the linker length but the inhibition pattern is opposing with the 1,2,3-triazoles
compared to the 1,2,4-triazoles. This selectivity for HDAC6 inhibition and SIRT1
activation makes these good molecules to consider optimizing to try to get the maximum
amount of inhibition or activation for each class of HDACs.
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Figure 9: HDAC1, HDAC6, and SIRT1 Assay Results: Results for 3a-c, 4a, 6a-b at a
final concentration of 25 uM. The results are represented with the standard
deviation of 3 independent trials.

Figure 10: HDAC1, HDAC6, and SIRT1 Assay Results: Results for Control
Compounds at a final concentration of 25 uM. The results are represented with
the standard deviation of 3 independent trials.
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Figure 11: HDAC1 Inhibition Graph with Various Compounds at 25 uM

Figure 12: HDAC6 Inhibition Graph with Various Compounds at 25 uM
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Figure 13: SIRT1 Inhibition Graph with Various Compounds at 25 uM

Conclusion
Though none of the synthesized compounds are strong activators or inhibitors of
any of the classes of HDACs there are definitely some observed trends. The 1,2,3triazoles and 1,2,4-triazoles do not have a specific pattern with HDAC1. There was not
much activity with the 1,2,3-triazoles or the 1,2,4-triazoles against SIRT1 but there was
a definite pattern within the molecules. As the linker increased in the 1,2,3-triazoles the
activation of SIRT1 also increased. The 1,2,4-triazoles showed an opposing pattern, as
the linker length increased the inhibition of SIRT1 increased. The best inhibition was
observed with HDAC6. The compounds appear to be selective at inhibiting HDAC6 as
compared to HDAC1. The compounds activated SIRT1 more than inhibited, thus
making the compounds more selective in favor of inhibiting HDAC6.
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Future Work
To further the study of HDAC1, HDAC6, and SIRT1 using triazoles as zinc
binding groups several changes can be studied with this class of molecules. The
substituents on both 1,2,3- and 1,2,4-triazoles need to be altered to determine if the zinc
binding can be increased or decreased (Figure 14). The studies with the 1,2,3-triazoles
that have the ‘side-arms’ appear to allow some inhibition control. The length of the
linkers in both the 1,2,3- and 1,2,4-triazoles can be changed to determine the optimal
length for each class of HDAC. The subsituents on the cap groups can also be changed
to increase the cap recognition region. Especially, for HDAC6 increasing the size of the
cap recognition region may further help it the compounds to become more selective.
The rigidity of the linker chain can be changed to determine if making the molecules
more like TSA rather than SAHA could increase the activity and maintain the selectivity.
Also, control compounds that mimic SAHA and previously synthesized compounds
found in literature that contain the desired linker length also need to be tested (Figure
14).

Figure 14: Future Compounds
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Experimental
Materials: 1H NMR and 13C NMR spectra were recorded using a Varian Inova
instrument operating at 600 MHz. Chemical shifts were reported in parts per million
(ppm) relative to deuterated solvent signal. High-resolution ESI mass spectra were
recorded using a JEOL AccuTOF MS (orthogonal TOF) instrument with DART source
calibrated with a PEG positive standard. Absorption spectra were collected on a Thermo
Scientific Evolution 600. Fluorescence Spectrometry was performed using a Perking
Elmer LS 55 instrument and/or a BioTek Synergy multimode plate reader. Flash column
chromatography was performed using standard grade silica 230 x 400 mesh from
sorbent technologies. Analytical thin-layer chromatography (TLC) was performed using
aluminum backed silica gel TLC plates with UV indicator from Sorbent Technologies.
The HDAC fluorimetric drug discovery kits for HDAC 1 and Sirtuin were purchased from
Biomol International. Recombinant HDAC 6 was also purchased from Biomol
International. Anhydrous solvents were purified using a Grubbs solvent system.
Reagent grade chemicals were used unless otherwise indicated.

WARNING: Low molecular weight azides are potentially explosive. Appropriate
safety emasures should always be taken when handling these compounds.

1a: 1,4-Diazidobutane: 1,4-Dibromobutane (2.00 g, 9.26 mmol)

was

dissolved in dimethylformamide (20.6 mL). Sodium Azide (23.2 mmol) was dissolved in
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water (2.57 mL) and added to the dibromide solution. The reaction stirred at room
temperature overnight (12-18 hours). Reaction progress was monitored by GC-MS.
Upon consumption of starting material, water was added to the reaction mixture. The
water was extracted with diethyl ether 3 times. The organic layers were combined and
rinsed with water 3 times, saturated copper (II) sulfate 1 time, and brine 1 time. The
organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in
vacuo. This material was used without further purification.

1b: 1,5-Diazidopentane: 1,5-Diazidopentane was prepared from 1,5dibromopentane as listed above for 1,4-Diazidobutane.

1c: 1,6-Diazidohexane: 1,6-Diazidohexane was prepared from 1,6dibromohexane as listed above for 1,4-Diazidobutane.

2a: 1-(4-azidobuty)-4-phenyl-1H-1,2,3-triazole: The 1,4-diazidobutane
(1.00 g, 7.14 mmol), phenylacetylene (0.290 g, 2.86 mmol), and triethylamine (398 uL,
2.86 mmol) were dissolved in acetonitrile (35.8 mL). 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-
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triazine (8.68 mg, 0.028 mmol) and tetrakis(acetonitrile-N)copper(I) tetrafluoroborate
(8.88 mg, 0.0280 mmol) were added to the reaction solution. The reaction was stirred at
room temperature overnight (12-18 hours). After concentration in vacuo the crude
product was purified via silica gel chromatography with a gradient elution using ethyl
acetate and hexanes.

2b:

1,5-(5-azidopentyl)-4-phenyl-1H-1,2,3-triazole:

1,5-(5-

azidopentyl)-4-phenyl-1H-1,2,3-triazole was prepared as listed above for 1-(4azidobuty)-4-phenyl-1H-1,2,3-triazole.

2c: 1,6-(6-azidohexyl)-4-phenyl-1H-1,2,3-triazole: 1,6-(6-azidohexyl)4-phenyl-1H-1,2,3-triazole was prepared as listed above for 1-(4-azidobuty)-4-phenyl1H-1,2,3-triazole.

3a: (1-(4-(4-phenyl-1H-1,2,3-triazole-1-yl)butyl)-1H-1,2,3-triazol-4yl)methanol: 1-(4-azidobuty)-4-phenyl-1H-1,2,3-triazole (0.400 g, 0.830 mmol),
propargyl alcohol (50.6 uL, 0.870 mmol),37and triethylamine (115 uL,0.830 mmol)

were dissolved in acetonitrile (5.53 mL). 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine
(26.1 mg, 0.083 mmol) and tetrakis(acetonitrile-N)copper(I) tetrafluoroborate (25.7 mg,
0.0830 mmol) were added to the reaction solution. The reaction was stirred at room
temperature overnight (12-18 hours). After concentration in vacuo the crude product
was purified via column chromatography with a gradient elution using ethyl acetate and
hexanes.
1

H NMR (d6-DMSO, 600 MHz) δ 7.72 (s, 1H), 7.12 (s, 1H), 7.00 (d, 2H, J= 12),

6.60 (t, 2H, J= 6), 6.49 (t, 1 H, J= 6), 4.31 (t, 1H, J= 6), 3.65 (d, 2H, J= 6), 3.59 (t, 3H, J=
6), 3.54 (t, 3H, J= 6), 3.25 (m, 2H), 2.32 (d, 3H, J= 6), 1.66 (m, 2H), 0.98 (m, 4H).
13

C NMR (DMSO, 151 MHz) δ147.9, 146.3, 130.7, 128.8, 127.8, 125.1, 122.6,

121.3, 55.0, 48.8, 48.6, 48.5, 26.8, 26.7.
HRMS (ESI) m/z calculated 299.16203 (C15H19N6O1, [M+H]+), m/z observed
299.16058( C15H19N6O1, [M+H]+. Mass Difference (ppm) -4.87.

3b:

(1-(5-(4-phenyl-1H-1,2,3-triazole-1-yl)pentyl)-1H-1,2,3-triazol-

4-yl)methanol:

(1-(5-(4-phenyl-1H-1,2,3-triazole-1-yl)pentyl)-1H-1,2,3-triazol-4-

yl)methanol was prepared as listed above for (1-(4-(4-phenyl-1H-1,2,3-triazole-1yl)butyl)-1H-1,2,3-triazol-4-yl)methanol.
1

H NMR (d6-DMSO, 600 MHz) δ 7.55 (s, 1H), 7.47 (d, 2H, J= 12), 7.25 (s, 1H),

7.06 (t, 2H, J= 6), 6.97 (t, 1H, J= 6), 4.35 (s, 2H), 4.04 (t, 2 H, J= 6), 3.99 (t, 2H, J=
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6), 3.02 (s, 1H), 1.61 (m, 4H), 0.99 (m, 2H).
13

C NMR (DMSO, 151 MHz) δ148.7, 147.5, 130.6, 128.8, 125.6, 121.9, 120.0,

56.2, 49.8, 49.7, 29.5, 29.4, 23.2.
HRMS (ESI) m/z calculated 313.17768 (C16H21N6O1, [M+H]+), m/z observed
313.17728 ( C16H21N6O1, [M+H]+. Mass Difference (ppm) -1.28.

3c: (1-(4-(6-phenyl-1H-1,2,3-triazole-1-yl)hexyl)-1H-1,2,3-triazol-4yl)methanol:

(1-(4-(6-phenyl-1H-1,2,3-triazole-1-yl)hexyl)-1H-1,2,3-triazol-4-

yl)methanol was also prepared as listed above for (1-(4-(4-phenyl-1H-1,2,3-triazole-1yl)butyl)-1H-1,2,3-triazol-4-yl)methanol.
1

H NMR (d6-DMSO, 600 MHz) δ 7.61 (s, 1H), 7.54 (d, 2H, J= 2), 7.30 (s, 1H),

7.14 (t, 2H, J= 6), 7.05 (t, 1H, J= 6), 4.46 (d, 2H, J= 6) , 4.11 (t, 2H, J= 6), 4.05 (t, 2H, J=
6), 3.12 (s, 1H), 1.67 (m, 2H), 1.62 (m, 2H), 1.10 (m, 4H).
13

C NMR (DMSO, 151 MHz) δ147.6, 130.7, 128.9, 128.1, 125.6, 121.8, 119.9,

56.3, 50.1, 49.9, 30.0, 25.8, 25.8.
HRMS (ESI) m/z calculated 327.1933 (C17H23N6O1, [M+H]+), m/z observed
327.19202 (C17H23N6O1, [M+H]+. Mass Difference (ppm) -4.03.
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4a:

2-(1-(6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexyl)-1H-1,2,3-triazol-

4-yl)ethanol:

2-(1-(6-(4-phenyl-1H-1,2,3-triazole-1-yl)hexyl)-1H-1,2,3-triazol-4-

yl)ethanol (0.400 g, 1.18 mmol), propargyl alcohol (89.3 uL, 1.18 mmol), and
trieithylamine (164 uL, 1.18 mmol) were dissolved in acetonitrile (7.86 mL). 5,6diphenyl-3-(pyridine-2-yl)-1,2,4-triazine

(5.58

mg,

0.0180

mmol)

and

tetrakis(acetonitrile-N)copper(I) tetrafluoroborate (5.65 mg, 0.0180 mmol) were added to
the reaction solution. The reaction was stirred at room temperature overnight (12-18
hours). After concentration in vacuo the crude product was purified via column
chromatography with a gradient elution using ethyl acetate and methanol.
1

H NMR (d6-DMSO, 600 MHz) δ7.62 (s, 1H), 7.56 (d, 2H, J= 12), 7.19 (d, 1H, J=

12), 7.16 (t, 2H, J= 6), 7.05 (t, 1H, J= 12), 4.14 (t, 2H, J= 12), 4.06 (t, 2H, J= 6), 3.69 (s,
2H), 3.13 (s, 1H), 2.67 (t, 2H, J= 12), 1.69 (t, 2H, J= 6), 1.63 (t, 2H, J= 6), 1.12 (m, 4H).
13

C NMR (DMSO, 151 MHz) δ 147.6, 130.7, 128.9, 128.1, 125.6, 119.9, 61.3,

50.1, 49.9, 30.0, 30.0, 29.1, 25.8.
HRMS (ESI) m/z calculated 341.20898 (C18H25N6O1, [M+H]+), m/z observed
341.20949 (C18H25N6O1, [M+H]+. Mass Difference (ppm) 1.48.
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5a: 5-bromo-N-phenylpentanamide: 5-bromopentanoic acid (1.00 g,
5.52 mmol) was dissolved in DCM (15.5 mL) with a catalytic amount of DMF (56.0 uL).
The reaction mixture was cooled to -5 oC. A solution of 2 M oxalyl chloride (532 uL, 6.09
mmol) in DCM (3.04 mL) was added drop wise to the reaction with vigorous stirring over
15 minutes. The suspension was warmed to room temperature and stirred for 1 hour.
The volatiles were evaporated under a stream of nitrogen. The residue was dissolved in
DCM (25.6 mL) and cooled to zero oC. DIEA (2.021 mL, 11.6 mmol) was added drop
wise. The aniline (504 uL, 5.52 mmol) was added drop wise over 1 hour. The reaction
mixture was warmed to room temperature after the addition of the aniline and the
reaction stirred for 2 hours.
The reaction was quenched by addition of water (5.00 mL). The solution was
extracted with DCM 2 times. The DCM layer was washed with saturated sodium
bicarbonate 2 times, water 1 time, 1M hydrochloric acid 2 times, and sodium chloride 1
time. The organic layer was dried over sodium sulfate, filtered and concentrated down in
vacuo.28

5b: 6-bromo-N-phenylhexanamide: 6-bromohexanoic acid was prepared
as listed above for 5-bromo-N-phenylpentanamide.28
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6a:

N-phenyl-5-(1H-1,2,4-triazol-1-yl)pentanamide:

5-bromo-N-

phenylpentamide (60.0 mg, 0.234 mmol), 1,2,4-1H-triazole (18.0 mg, 0.258 mmol), and
freshly ground potassium carbonate (36.0 mg, 0.258 mmol) were dissolved in DMF
(669.0 uL). The reaction stirred at room temperature overnight (12-14 hours). The
reaction was quenched with water (5.0 mL). The water was extracted with ethyl acetate
3 times. The organic layers were combined and washed with brine 1 time. The organic
layer was dried over sodium sulfate, filtered and concentrated in vacuo.
1

H NMR (CDCl3, 600 MHz) δ 8.29 (s, 1H), 8.09 (s, 1H), 7.93 (s, 1H), 7.48 (d, 1H,

J= 6), 7.27 (t, 2H, J= 6), 7.07 (t, 2H, J= 6), 4.16 (t, 2H, J= 6), 2.36 (t, 2H, J= 6), 1.94 (m,
2H), 1.69 (m, 2H).
13

C NMR (CDCl3, 151 MHz) δ 171.1, 151.7, 143.1, 137.9, 129.0, 124.5, 120.1,

49.3, 36.4, 29.2, 22.3.
HRMS (ESI) m/z calculated 245.14024 ( C13H17N4O1, [M+H]+), m/z observed
245.13918 (C13H17N4O1, [M+H]+. Mass Difference (ppm) -4.31.

6b:

N-phenyl-6-(1H-1,2,4-triazol-1-yl)hexanamide:

6-bromo-N-

phenylhexanamide was prepared as listed above for N-phenyl-5-(1H-1,2,4-triazol-1yl)pentanamide.
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1

H NMR (CDCl3, 600 MHz) δ 8.16 (s, 1H), 8.05 (s, 1H), 7.40 (s, 1H), 7.50 (d, 1H,

J= 6), 7.29 (t, 2H, J= 12), 7.08 (t, 2H, J= 6), 4.17 (t, 2H, J= 6), 2.35 (t, 2H, J= 12), 1.94
(m, 2H), 1.76 (m, 2H), 1.36 (m, 2H).
13

C NMR (CDCl3, 151 MHz) δ166.2, 147.3, 138.4, 133.3, 124.4, 119.7, 115.2,

44.8, 32.6, 24.9, 21.4, 20.1.
HRMS (ESI) m/z calculated 259.15589 ( C14H19N4O1, [M+H]+), m/z observed
259.15473 (C14H19N4O1, [M+H]+. Mass Difference (ppm) -4.48.

7a:

(Z)-

5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine.

picolinohydrazonamide (500.0 mg, 3.67 mmol) and benzil (772 mg, 3.67 mmol) were
added to 10 mL of ethanol. The slurry was heated at 80 °C for 6 h with complete
dissolution. Progress of the reaction was monitored by TLC. The reaction mixture was
cooled to room temperature and the resulting precipitate was filtered and washed with
ethanol and ether resulting in a 76% yield.
1

H NMR (CDCl3, 600 MHz) δ 8.91 (d, 1H, J = 4.2 Hz), 8.70 (d, 1H, J = 7.8 Hz),

7.91 (t, 1H, J = 7.8 Hz), 7.68 (d, 2H, J = 7.8 Hz), 7.64 (d, 2H, J = 7.8 Hz), 7.46 (t, 1H, J
= 6.6 Hz), 7.43-7.31 (m, 6H).
13

C NMR (CDCl3, 151 MHz) δ 160.7, 156.4, 156.3, 152.8, 150.4, 137.0, 135.6,

135.2, 130.6, 129.9, 129.7, 129.5, 128.5, 128.5, 125.3, 124.1.
HRMS

(ESI)

m/z

calculated
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311.12967

(C20H15N4,

[M+H]+),

m/z

observed 311.12831 (C20H15N4, [M+H]+)

Fluorimetric HDAC Assay: The procedure was followed for HDAC 1, 6 and
Sirtuin as listed by Biomol with the following specifications. HDAC 1 and 6: To the
appropriate wells, 4 uL of the test inhibitor was added to obtain a 25 uM final
concentration. HDAC assay buffer II was warmed for 10 minutes. The chilled enzyme
was diluted with the warm buffer and added to the wells to have a final concentration of
0.2 ug/well. The substrate was diluted in the warm assay buffer and added to
appropriate wells to give a final concentration of 20 uM. The reaction was incubated at
37 oC for 30 minutes. After the 37oC incubation, 20 uL of the 5x developer solution with
1% TSA was added to all of the wells and incubated in the dark for 45 minutes at room
temperature. The samples were diluted appropriately (any where from 1 to 10 fold with
nano-pure water) to be read with an excitation of 360 nm and an emission of 460 nm on
the fluorometer. If the samples were read on the plate reader, a dichroic mirror was
used with 80% sensitivity. The plates were white and were read with an excitation of
360/40 and had an emission of 440/30. The data were processed using Microsoft Excel.
SIRT 1: The protocol for the sirtuins is very similar to the HDAC 6 and 1. To the
appropriate wells, 4 uL of compound was added to have a 25 uM final concentration.
Followed by 6 uL of 20 % NAD+ in substrate was added to have a final concentration of
125 uM and 500 uM respectively. HDAC assay buffer II and the above assay mix was
warmed for 10 minutes. The enzyme was added to the warm buffer and added to the
wells to have a final concentration of 0.04 U/well. The reaction incubated at 37 oC for 30
minutes. After the 37 oC incubation, 20 uL of the 5x developer solution with 1% TSA
44

was added to all of the wells and incubated in the dark for 45 minutes at room
temperature. The samples were diluted appropriately and read as listed for HDAC 1 and
6.
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